Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ EBITDA Margin

EBITDA as a percentage of revenue.

Johnson & JohnsonNYSE: JNJ

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to 25.1%

EBITDA Margin was 25.1% in Q3 FY2026, down 13.7 pp from a year earlier. On a trailing-twelve-month basis it was 31.0%, down 11.9 pp year over year. Over 3 fiscal years it widened by 10.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 16 analysts of 37.0% for the fiscal year ending Dec 2026, down from 43.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
25.1%-10.4 pp QoQ
Last fiscal yearDec 2025
43.6%+15.7 pp YoY
LTMSep 2026
31.0%-11.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-13.7 pp+9.0 pp+22.6 pp
1 year+15.7 pp-6.6 pp-22.3 pp
3 years+10.3 pp-5.8 pp-16.2 pp
5 years-4.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
43.6%
Year-over-year change
+15.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How JNJ compares with its peers on the latest reported figures

  • JNJ's LTM Sep 2026 EBITDA Margin of 31.0% is the 6th highest of the 11 companies compared; the peer median is 32.2%.
  • Its year-over-year change of -11.9 pp is the 9th highest of 11, against a peer median of -0.1 pp.
  • Over three fiscal years its change of +10.3 pp compares with a peer median of +1.1 pp.
JNJ Competitors Peer median
EBITDA Margin for JNJ and competitors
Company Period LTM level YoY 3-year change
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
ABBVAbbVie Inc.LTM Sep 202636.6% +15.1 pp-12.8 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202634.2% +2.6 pp-10.0 pp
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
SNYSanofiLTM Jun 202630.2% +0.6 pp-6.6 pp
GSKGSK plcLTM Jun 202626.5% -0.7 pp+2.5 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
GILDGilead Sciences, Inc.LTM Jun 20264.4% -33.6 pp+13.7 pp
Peer median (excluding JNJ) 32.2%-0.1 pp+1.1 pp

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.74B79.99B85.16B88.82B94.19B
Cost of Revenue23.4B24.6B26.55B27.47B30.26B
Gross Profit55.34B55.39B58.61B61.35B63.94B
Gross Margin70.3%69.3%68.8%69.1%67.9%
Research & Development14.28B14.14B15.09B17.23B14.67B
Selling, General & Admin20.12B20.25B20.11B21.97B23.68B
Operating Expenses34.4B34.38B35.2B39.2B38.34B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
EBITDA26.75B26.61B23.32B24.78B41.06B
EBITDA Margin34.0%33.3%27.4%27.9%43.6%
Operating Income20.94B21.01B23.41B22.15B25.6B
Operating Margin26.6%26.3%27.5%24.9%27.2%
Interest Income53M490M1.26B1.33B1.06B
Interest Expense183M276M772M755M971M
Other Income / Expenses(1.77B)(1.65B)(8.35B)(5.46B)6.99B
Income Before Tax19.18B19.36B15.06B16.69B32.58B
Pre-Tax Margin24.4%24.2%17.7%18.8%34.6%
Income Tax Expense1.38B2.99B1.74B2.62B5.78B
Net Income20.88B17.94B35.15B14.07B26.8B
Net Margin26.5%22.4%41.3%15.8%28.5%
EPS (Basic)7.936.8313.885.8411.03
EPS (Diluted)7.816.7313.725.7911.03
Weighted Avg Shares2.63B2.61B2.53B2.41B2.43B
Weighted Avg Shares (Diluted)2.67B2.66B2.56B2.43B2.43B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.